Printed From BioPortfolio.com

Critical Outcome Technologies Announces Pharmacodynamic Data and Positive Signals of Efficacy ...

07:00 EST 19 Dec 2017 | BioMedReports - Blog

Establishes recommended Phase 2 dose in ovarian cancer based on strong safety, tolerability and pharmacokinetic data

LONDON, ONTARIO and BOSTON, MASSACHUSETTS--(Marketwired - Dec. 19, 2017)

More From BioPortfolio on "Critical Outcome Technologies Announces Pharmacodynamic Data and Positive Signals of Efficacy ..."

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topic

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women. Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches

Topics

Critical Outcome Technologies Announces Pharmacodynamic Data and Positive Signals of Efficacy ...

More From BioPortfolio on "Critical Outcome Technologies Announces Pharmacodynamic Data and Positive Signals of Efficacy ..."

Relevant Topic

News Quicklinks